Relay Therapeutics Hits New 52-Week High After Analyst Upgrade

Barclays raises price target on biotech stock to $21, citing promising pipeline.

Apr. 10, 2026 at 5:04am

Got story updates? Submit your updates here. ›

An extreme close-up of intricate pharmaceutical manufacturing equipment, pipes, and machinery, conveying the complex, industrial nature of drug development.Relay Therapeutics' advanced drug discovery platform relies on cutting-edge pharmaceutical technology to develop innovative cancer treatments.Cambridge Today

Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) reached a new 52-week high after Barclays upgraded the stock and raised its price target from $17 to $21. The biotech company, which is focused on developing precision cancer therapies, saw its stock surge on the positive analyst report.

Why it matters

Relay Therapeutics is a clinical-stage biotech company with a unique drug discovery platform that leverages computational modeling and structural biology to identify promising small-molecule drug candidates. The analyst upgrade and new 52-week high suggest growing investor confidence in the company's pipeline and future growth potential.

The details

Barclays maintained an 'overweight' rating on Relay Therapeutics and raised its price target from $17 to $21 per share. The investment bank cited the company's promising pipeline and drug discovery capabilities as reasons for the upgrade. Relay Therapeutics' share price hit $14.64 during intraday trading, a new 52-week high for the stock.

  • Relay Therapeutics' share price hit a new 52-week high during mid-day trading on Thursday, April 10, 2026.
  • Barclays raised its price target on Relay Therapeutics from $17 to $21 on the same day.

The players

Relay Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing precision therapies for oncology. The company leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates.

Barclays

A multinational investment bank and financial services company that provides research coverage and analysis on Relay Therapeutics.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Relay Therapeutics' progress as it continues to advance its pipeline of precision cancer therapies. The company's next major milestone will be the release of additional data from its ongoing clinical trials, which could further boost investor confidence and the stock price.

The takeaway

The analyst upgrade and new 52-week high for Relay Therapeutics' stock price reflect growing optimism around the company's unique drug discovery platform and its potential to develop innovative cancer treatments. As a clinical-stage biotech, Relay Therapeutics remains a high-risk, high-reward investment, but the positive momentum suggests the company is making promising strides in its mission.